Home
About Us
    About YolTech
    Leadership
    Advisory Board
    Investors
Science
    Genome Editing Platform
    LNP Delivery Platform
Pipeline
    Pipeline
        Metabolic Disease
        Genetic Disease
        Infectious Disease
    Disease
        Familial Hypercholesterolemia (FH)
        Hereditary Transthyretin Amyloidosis (ATTR)
        Atherosclerotic Cardiovascular Disease (ASCVD)
        Primary Hyperoxaluria (PH1)
        Hereditary Angioedema (HAE)
        Hepatitis B
News
    Press Release
        YolTech Completes Dose Escalation in YOLT-201 Phase I Trial
        YolTech and East China Normal University Publish Breakthrough Study on In Vivo Genome Editing for Blood Disorders
        YolTech Awarded Patent for Novel Lipid Nanoparticle Technology, Strengthening In-House Delivery Capabilities
        YolTech Publish Breakthrough Research on Novel Gene-Editing Strategy for Treating Primary Hyperoxaluria Type 1 in Molecular Therapy
        YolTech Receives U.S. FDA ODD for YOLT-203 in Treating PH1
        YolTech Receives U.S. FDA RPDD for YOLT-203 in Treating PH1
        YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China
        YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1
        First Patient Dosed in Phase I Clinical Trial of YOLT-201
        YolTech and Wimi Bio Form Licensing Partnership to Advance Gene Editing Technology in Agriculture
        YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China
        YolTech Secures Patent for Innovative DNA Editing System
        First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH
        YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
        Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
        YolTech Gains Patent for Advanced Base Editing Technology
        YolTech Announces Appointment of Tony W.Ho as Scientific Advisor
        First Patient Dosed in Clinical Trial of YOLT-201 for ATTR-CM
        YolTech’s Founder Interviewed by UCB China Voice Journal
        YolTech Announces NMPA Acceptance of IND Application for YOLT-201 to Treat hATTR
        YolTech Secured $15 Million in Series A+ Financing
    Media Release
        CDE Clears IND Application for Therapeutic Candidate Targeting ATTR
        YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
        Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
        Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
        YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024
        First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
    Publication
Career
    Corporate Culture
    Job Opportunites
Contact Us
    contact